Deep Intelligent Pharma

About Deep Intelligent Pharma

Deep Intelligent Pharma (DIP), established in Beijing in September 2017, operates at the intersection of artificial intelligence and pharmaceutical research. The company was founded by Li Xing, who serves as the CEO. Li, a graduate of Peking University's School of Pharmaceutical Sciences, accumulated over 12 years of experience in new drug development at multinational corporations like Pfizer, Sanofi, and Johnson & Johnson, where he spearheaded Johnson & Johnson's first AI project in the Asia-Pacific region. This background in both pharmacology and AI implementation provided the foundational expertise for DIP's mission.

The firm provides an AI-native, multi-agent platform designed to address the entire drug research and development lifecycle, from discovery to regulatory submission. Its business model focuses on providing AI-as-a-Service (AIaaS) solutions to a client base of over 1,000 global pharmaceutical companies and biotechs. By targeting the inefficiencies inherent in traditional drug development, DIP aims to significantly reduce the time and costs associated with bringing new medicines to market. The company has secured significant venture capital, including a Pre-A round from ZhenFund in 2017 and a substantial Series B round led by Sequoia China.

DIP's core offering is a suite of AI-driven tools that reimagine pharmaceutical R&D processes. The platform features an AI-powered organic synthesis system that assists chemists by generating optimized retrosynthesis routes for target compounds. Its services extend to intelligent medical writing, multi-language medical machine translation, and pharmacovigilance for risk management. A key differentiator is its focus on creating a unified ecosystem for both structured and unstructured data, allowing for natural language queries and autonomous data management, which revolutionizes clinical trial workflows and automates regulatory documentation. The company's technology has gained international recognition, demonstrated by its presentation at a Microsoft Build conference, where it showcased how its platform enabled a partner's clinical trial protocol to pass Japan's stringent PMDA review on the first attempt.